Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

17.0%

8 terminated/withdrawn out of 47 trials

Success Rate

82.2%

-4.3% vs industry average

Late-Stage Pipeline

9%

4 trials in Phase 3/4

Results Transparency

8%

3 of 37 completed trials have results

Key Signals

2 recruiting3 with results6 terminated

Enrollment Performance

Analytics

Phase 1
26(57.8%)
Phase 2
9(20.0%)
N/A
6(13.3%)
Phase 4
4(8.9%)
45Total
Phase 1(26)
Phase 2(9)
N/A(6)
Phase 4(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (47)

Showing 20 of 47 trials
NCT06611930Phase 2Terminated

CK-0045 Proof-of-concept Study in Participants With Overweight / Obesity and Type 2 Diabetes

Role: collaborator

NCT06439056Phase 1Completed

Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D

Role: collaborator

NCT07146347Phase 1Recruiting

Comparison Study of Insulin GZR4 With Insulin Degludec

Role: collaborator

NCT06758583Phase 1Completed

A Trial Comparing Pharmacokinetics, Safety and Tolerability of Two Subcutaneous Concentrations of Dapiglutide

Role: collaborator

NCT06000891Phase 1Terminated

A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570

Role: collaborator

NCT06272136Not ApplicableRecruiting

Liom Non-invasive Continuous Glucose Monitor "Clinical Demo" (niCGM)

Role: collaborator

NCT01906970Not ApplicableCompleted

Clinical Experimental Study to Investigate Specific Features of ClampArt®

Role: lead

NCT05413863Phase 1Completed

Comparison of the Pharmacokinetic and Pharmacodynamic Properties of Biocon's Insulin R U-500 With Humulin® R U-500 (US Reference Product) in Healthy Subjects

Role: collaborator

NCT04141423Phase 1Terminated

Evaluation of Pharmacokinetics , Safety, Tolerability and Pharmacodynamics of Biocon Insulin Tregopil

Role: collaborator

NCT01910051Completed

Explorative Assessment of Biomarkers in Overweight and Obese Subjects

Role: lead

NCT02518581Not ApplicableCompleted

Validation of the Doubly Labelled Water Method in Subjects With Type 2 Diabetes Mellitus

Role: lead

NCT04022317Phase 1Completed

Comparision of Pharmacokinetics(PK) and Pharmacodynamics(PD) of Biocon Insulin R and Humulin® R

Role: collaborator

NCT03359590Phase 2Completed

Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients

Role: lead

NCT03907202Phase 1Terminated

A Clinical Study to Evaluate the Safety, Tolerability, PK, PD, and Efficacy of KBP-089 in Patients With T2DM

Role: collaborator

NCT02206568Phase 1Withdrawn

Pharmacokinetics of Ultra-Rapid-Acting Insulin Lispro (URAL) in Type 1 Diabetes Mellitus

Role: collaborator

NCT03254849Phase 4Completed

Empagliflozin and Sympathetic Nerve Traffic

Role: lead

NCT02634528Phase 1Completed

Pharmacokinetic (PK) Bioequivalence and Pharmacodynamics (PD) of Julphar Insulin N and Huminsulin® Basal

Role: collaborator

NCT02737891Phase 2Completed

Safety and Efficacy Study of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus

Role: collaborator

NCT04022291Phase 1Completed

Comparison of Pharmacokinetic (PK) and Pharmacodynamic(PD) of Biocon Insulin 70/30 and Humulin® 70/30

Role: collaborator

NCT04022304Phase 1Completed

Comparision of Pharmacokinetic and Pharmacodynamic of Biocon Insulin N and Humulin® N

Role: collaborator